期刊
THROMBOSIS RESEARCH
卷 116, 期 1, 页码 41-50出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.thromres.2004.10.004
关键词
low-molecular-weight heparin; impaired renal function; obesity; anticoagulant; anti-Xa activity
Background: Enoxaparin dosage for obese patients and patients with renal impairment remains controversial. Objective: To compare anti-factor Xa activity (anti-Xa) among obese and renal impairment patients to patients with healthy weight and adequate renal function. Design: Open, prospective, nonrandomized clinical trial. Setting: A major community teaching hospital. Patients: A total of 233 patients with prescription of enoxaparin. Interventions: Enoxaparin 1.5 mg/kg once daily or 1 mg/kg twice daily except those on dialysis, who received 75% of the dose. Measurements: Anti-Xa was measured 4 h post-injection on day 2 or 3. Results: Mean (95% confidence interval (95% Cl)) anti-Xa was equal to 1.14 IU/mL (1.07-1.21) and 1.14 IU/mL (1.08-1.20) among patients who received one (n=92) and two injections (n=122) per day, respectively. Anti-Xa increases with body mass index (BMI) (0.01 IU/mL for each kg/m(2); 95% CI: 0.002-0.017), but the increase is insufficient to reach supratherapeutic anti-Xa. Anti-Xa decreases with higher creatinine clearance (CrCl) (-0.003 IU/mL for each mL/min; 95% CI: -0.006 to -0.001). On the twice-daily regimen, this is sufficient to reach supratherapeutic anti-Xa. The odd ratio (OR) (95% Cl) of having a nontherapeutic anti-Xa is equal to 2.28 (1.25-4.16) when enoxaparin is administered twice daily and to 3.03 (1.16-7.86) among severe renal impairment patients (:<= 30 mL/min). Conclusions: Based on Anti-Xa, no dosage adjustments are required in obese patients. In renally impaired patients, adjustments may be necessary when enoxaparin is administered twice daily. (c) 2004 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据